EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) 3-Year EPS without NRI Growth Rate: 51.10% (As of Jun. 2026)— 24% Above Median
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's average EPS without NRI Growth Rate was -254.50% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 51.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS 3-Year EPS without NRI Growth Rate Related Terms
IST:ECILC vs ZTS, UTHR, VTRS: 3-Year EPS without NRI Growth Rate Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
* The bar in red indicates where EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's 3-Year EPS without NRI Growth Rate falls into.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 51.10% mean?
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) has a 3-Year EPS without NRI Growth Rate of 51.10% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS and its competitors. This is 24% above median its historical median of 41.30. According to the industry distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #94 out of 785 companies in the Drug Manufacturers industry, placing it in the top 12%.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's 3-Year EPS without NRI Growth Rate too high?
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current 3-Year EPS without NRI Growth Rate of 51.10% is 24% above median its 10-year median of 41.30. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.70. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's value of 51.10% is 426.8% above this industry median. Based on the distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #94 out of 785 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's 3-Year EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS ranks #94 out of 785 companies for 3-Year EPS without NRI Growth Rate. This places EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.70. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's value of 51.10% is 426.8% above this benchmark. While the company's 10-year median is 41.30 vs. the industry median of 9.70, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current 3-Year EPS without NRI Growth Rate of 51.10% is 426.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's current 3-Year EPS without NRI Growth Rate is 51.10%, which is 24% above median its own 10-year median of 41.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺60.82, compared to a current price of ₺78.30 — trading 28.7% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 51.10%, which is 24% above median its 10-year median of 41.30 and 426.8% above the Drug Manufacturers industry median of 9.70. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC), the current 3-Year EPS without NRI Growth Rate is 51.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) Overvalued in 2026?
Based on GuruFocus' analysis, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺78.30 is trading 28.7% above its estimated GF Value™ of ₺60.82.
GuruFocus considers EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS to be Modestly Overvalued.
Key valuation signals for IST:ECILC:
3-Year EPS without NRI Growth Rate: 51.10% (24% above median its 10-year median of 41.30)
GF Value™: ₺60.82 vs. price of ₺78.30 (28.7% above fair value)
Industry Position: 426.8% above the Drug Manufacturers median (#94 of 785)
No single metric tells the full story. See the IST:ECILC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is a Turkey-based company that operates in the drug business. It is mainly involved in the manufacturing of pharmaceuticals, veterinary drugs, and personal care products. Further, the group is also engaged in real estate development and leasing commercial property activities. Geographically, all the activities are carried out through the region of Turkey.
62GF Score
Get the complete analysis for IST:ECILC
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ECILC has been successfully added to your 
